Pharmacokinetic-pharmacodynamic crisis in the elderly

American Journal of Therapeutics

Volumn 14, Issue 5, 2007, Pages 488-498

  Eldesoky, Ehab S ^a  

^a Assiut University Faculty of Medicine   (Egypt)

Author keywords

Aging; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE; AMITRIPTYLINE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARBAMAZEPINE; CELECOXIB; DICLOFENAC; DOXORUBICIN; ERYTHROMYCIN; HALOPERIDOL; IBUPROFEN; IMIPRAMINE; LABETALOL; LIDOCAINE; METOPROLOL; MIDAZOLAM; MORPHINE; NIFEDIPINE; OMEPRAZOLE; OPIATE; PETHIDINE; PHENAZONE; PHENYTOIN; PROPRANOLOL; PSYCHOTROPIC AGENT; RISPERIDONE; UNINDEXED DRUG; VANCOMYCIN; VERAPAMIL;

AGING; BRAIN FUNCTION; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; DATA ANALYSIS; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG SENSITIVITY; FUNCTIONAL STATUS; GERIATRICS; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; KIDNEY; LIVER METABOLISM; LOW DRUG DOSE; MEDLINE; MENTAL DISEASE; ORTHOSTATIC HYPOTENSION; POSTOPERATIVE PAIN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; WATER CONTENT;

AGED; AGING; CARDIOVASCULAR AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; DRUG THERAPY; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY;

EID: 34748874678     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000183719.84390.4d     Document Type: Review

References (118)

1. Liew CC. Biochemical aspects of aging. In: Gornall AG, ed. Applied Biochemistry of Clinical Disorders. 2nd ed. Philadelphia: Lippincott Raven Press; 1986:558-565.
2. Rattan SI. Aging: a biological perspective. Mol Aspects Med. 1995;16:439-508.
3. Greengross S, Murphy E, Quam L, et al. Aging: a subject that must be at top of world agendas. BMJ. 1997;315:1029-1030.
4. Crome P, Flanagan RJ. Pharmacokinetic studies in elderly people: are they necessary? Clin Pharmacokinet. 1994;26:243-247.
5. Grune T, Merker K, Jung T, et al. Protein oxidation and degradation during postmitotic senescence. Free Radic Biol Med. 2005;39:1208-1215.
6. Richter C. Oxidative damage to mitochondrial-DNA and its relationship to aging. Int J Biochem Cell B. 1995;27:647-653.
7. Kim H-J, Chung H-Y. Molecular exploration of age-related NFκB/IKK downregulation by calorie restriction in rat kidney. Free Rad Biol Med. 2002;32:991-1005.
8. Kim HJ, Jung KJ, Seo AY, et al. Calorie restriction modulates redox-sensitive AP-1 during the aging process. J Am Aging Assoc. 2002;25:123-130.
9. Sitte N, Merker K, Grune T, et al. Lipofuscin accumulation in proliferating fibroblasts in vitro: an indicator of oxidative stress. Exp Gerontol. 2001;36:475-486.
10. Zarling EJ, Mobarhan S, Bowan P. Pulmonary pentane excretion increases with age in healthy subjects. Mech Aging Dev. 1993;67:141-147.
11. Higami Y, Shimokawa I. Apoptosis in the aging process. Cell Tissue Res. 2002;301:125-132.
12. Anglade P, Vyas S, Hirsch EC, et al. Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol Histopathol. 1997;12:603-610.
13. McLean AJ, Le Couteur DG. Aging, biology, and geriatric clinical pharmacology. Pharmacol Rev. 2004;56:163-184.
14. Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly: clinical implications. Clin Pharmacokinet. 1998;35:49-64.
15. Abrams WB, Beers MH. Clinical pharmacology in an aging population. Clin Pharmacol Ther. 1998;63:281-284.
16. Flammiger A, Maibach H. Drug dosage in the elderly: dermatological drugs. Drugs Aging. 2006;23:203-215.
17. Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol. 2001;15:897-918.
18. Klotz U. Effect of aging on the pharmacokinetics of gastrointestinal drugs. In: Pilotto A, Malfertheiner P, Holt PR, eds. Aging and the Gastrointestinal Tract. Vol. 32. Basel: Interdiscipl Top Gerontol, Karger; 2003:28-39.
19. Turnheim K. Drug dosage in the elderly. Is it rational? Drugs Aging. 1998;13:357-379.
20. Wilkinson GR. The effects of diet, aging, and disease-states on presystemic elimination and oral drug bioavailability in humans. Adv Drug Deliv Rev. 1997;27:129-159.
21. Brenner SS, Klotz U. P-glycoprotein function in the elderly. Eur J Clin Pharmacol. 2004;60:97-102.
22. Toornvliet R, van Berckel BN, Luurtsema G, et al. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther. 2006;79:540-548.
23. Klotz U, Avant GR, Hoyumpa A, et al. The effect of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest. 1975;55:347-59.
24. Schmucker DL. Liver function and phase I drug metabolism in the elderly. Drugs Aging. 2001;18:837-851.
25. Grandison MK, Boudinot FD. Age-related changes in protein binding of drugs: implications for therapy. Clin Pharmacokinet. 2000;38:271-290.
26. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115-21.
27. Kitani K. Hepatic drug metabolism in the elderly. Hepatology. 1986;6:316-319.
28. Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly: an update. Clin Pharmacokinet. 1997;33:302-312.
29. LeCouteur DG, McLean AJ. The aging liver. Drug clearance and oxygen diffusion hypothesis. Clin Pharmacokinet. 1998;34:359-373.
30. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38:843-853.
31. Wynne H. Drug metabolism and ageing. J Br Menopause Soc. 2005;11:51-56.
32. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270:414-423.
33. Parkinson A, Mudra DR, Johnson C, et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol. 2004;199:193-209.
34. Ogura C, Kishimoto A, Mizukawa R, et al. Age differences in effects on blood pressure, flicker fusion frequency, salivation and pharmacokinetics of single oral doses of dothiepin and amitriptyline. Eur J Clin Pharmacol. 1983;25:811-814.
35. Greenblatt DJ, Abernethy DR, Matlis R, et al. Absorption and disposition of ibuprofen in the elderly. Arthritis Rheum. 1984;27:1066-1069.
36. Randolph WC, Seaman JJ, Dickson B, et al. The effect of age on theophylline clearance in normal subjects. Br J Clin Pharmacol. 1986;22:603-605.
37. Durnas C, Loi CM, Cusack BJ. Hepatic drug metabolism and ageing. Clin Pharmacokinet. 1990;19:359-389.
38. Tassaneeyakul W, Veronese ME, Birkett DJ. Co-regulation of phenytoin and tolbutamide metabolism in humans. Br J Clin Pharmacol. 1992;34:494-498.
39. George J, Byth K, Farrell GC. Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol. 1995;50:727-730.
40. Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther. 1998;23:247-255.
41. Simon T, Becquemont L, Hamon B, et al. Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers. Br J Clin Pharmacol. 2001;52:601-604.
42. Battino D, Croci D, Rossini A, et al. Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. Epilepsia. 2003;44:923-929.
43. Bebia Z, Buch SC, Wilson JW, et al. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther. 2004;76:618-627.
44. Gorski JC, Vannaprasaht S, Hamman MA, et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther. 2003;74:275-87; erratum, 2004;75:249.
45. Aichhorn W, Weiss U, Marksteiner J, et al. Influence of age and gender on risperidone plasma concentration. J Psychopharmacol. 2005;19:395-401.
46. Ishizawa Y, Yasui-Furukori N, Takahata T, et al. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Clin Pharmacokinet. 2005;44:1179-1189.
47. McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet. 1991;21:42-69.
48. Wynne HA, Cope LH, Herd B, et al. The association of age and frailty with paracetamol conjugation in man. Age Ageing. 1990;19:419-424.
49. Shah RR. Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II). Br J Clin Pharmacol. 2004;58:452-469.
50. Paris OL, Kupelian PA, Hall JM, et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev. 1999;8:901-905.
51. Bangsi D, Zhou J, Sun Y, et al. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men. Urol Oncol. 2006;24:21-27.
52. Ohara K, Tanabu S, Ishibashi K, et al. Effects of age and the CYP2D6*10 allele on the plasma haloperidol concentration/dose ratio. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:347-350.
53. Brenner SS, Herrlinger C, Dilger K, et al. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin Pharmacokinet. 2003;42:283-292.
54. Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology. 1999;45:243-253.
55. Morike K, Schwab M, Klotz U. Use of aminoglycosides in Elderly patients. Pharmacokinetic and clinical considerations. Drugs Aging. 1997;10:259-277.
56. Hoey LL, Tschida SJ, Rotschafer JC, et al. Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries. J Burn Care Rehabil. 1997;18:116-124.
57. Lackner TE, Birge S. Accuracy of pharmacokinetic dose determination of gentamicin in geriatric patients. DICP. 1990;24:29-32.
58. el-Sayed YM. Correlation between nephrotoxicity and pharmacokinetic parameters of gentamicin. J Clin Pharm Ther. 1994;19:267-271.
59. Peterson AK, Duffull SB. Population analysis of once-daily dosing of gentamicin in patients with neutropenia. Aust N Z J Med. 1998;28:311-315.
60. Ordovas JP, Ronchera CL, Poveda JL, et al. Selection of optimal prophylactic aminoglycoside dosage in cancer patients: population pharmacokinetic approaches. J Clin Pharm Ther. 1994;19:47-56.
61. Zaske DE, Irvine P, Strand LM, et al. Wide interpatient variations in gentamicin dose requirements for geriatric patients. JAMA. 1982;248:3122-3126.
62. Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology. 1999;45:243-253.
63. Feely J, Coakley D. Altered pharmacodynamics in the elderly. Clin Geriatr Med. 1990;6:269-283.
64. Zhang X. Cholinergic activity and amyloid precursor protein processing in aging and Alzheimer's disease. Curr Drug Targets CNS Neurol Disord. 2004;3:137-152.
65. Tayebati SK, Di Tullio MA, et al. Age-related changes of muscarinic cholinergic receptor subtypes in the striatum of Fisher 344 rats. Exp Gerontol. 2004;39:217-223.
66. Clader JW, Wang Y. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease. Curr Pharm Des. 2005;11:3353-3361.
67. Brodde OE, Leineweber K. Autonomic receptor systems in the failing and aging human heart: similarities and differences. Eur J Pharmacol. 2004;500:167-176.
68. Oberhauser V, Schwertfeger E, Rutz T, et al. Acetylcholine release in human heart atrium: influence of muscarinic autoreceptors, diabetes and age. Circulation. 2001;103:1638-1643.
69. Jones PP, Christou DD, Jordan J, et al. Baroreflex buffering is reduced with age in healthy men. Circulation. 2003;107:1770-1774.
70. Passmore JC, Joshua IG, Rowell PP, et al. Reduced alpha adrenergic mediated contraction of renal preglomerular blood vessels as a function of gender and aging. J Cell Biochem. 2005;96:672-681.
71. Andros E, Detmar-Hanna D, Suteparuk S, et al. The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. Eur J Clin Pharmacol. 1996;50:41-46.
72. Ferrara N, Davia K, Abete P, et al. Alterations in β-adrenoceptor mechanisms in the aging heart. Relationship with heart failure, aging. Clin Exp Res. 1997;9:391-403.
73. Roth DA, White CD, Podolin DA, et al. Alterations in myocardial signal transduction due to aging and chronic dynamic exercise. J Appl Physiol. 1998;84:177-184.
74. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2003;56:254-260.
75. Igawa Y, Yamazaki Y, Takeda H, et al. Functional and molecular or biological evidence for a possible β3-adrenoceptor in the human detrusor muscle. Br J Pharmacol. 1999;126:819-825.
76. Madersbacher S, Pycha A, Schatzl G, et al. The aging lower urinary tract: a comparative urodynamic study of men and women. Urology. 1998;51:206-212.
77. Li G, Li K, Li Z, et al. Age-dependent changes in β-adrenoceptor function in human detrusors and possible mechanisms. Chin Med J (Engl). 2003;116:1511-1514.
78. Narita M, Funada M, Suzuki T. Regulations of opioid dependence by opioid receptor types. Pharmacol Ther. 2001;89:1-15.
79. Smith MA, Gray JD. Age-related differences in sensitivity to the antinociceptive effects of opioids in male rats: influence of nociceptive intensity and intrinsic efficacy at the mu receptor. Psychopharmacology. 2001;156:445-453.
80. Meltzer CC, Smith G, DeKosky ST, et al. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology. 1998;18:407-430.
81. Narita M, Kuzumaki N, Narita M, et al. Age-related emotionality is associated with cortical delta-opioid receptor dysfunction-dependent astrogliosis. Neuroscience. 2006;137:1359-1367.
82. Filliol D, Ghozland S, Chluba J, et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet. 2000;25:195-200.
83. Klotz U. Effect of age on pharmacokinetics and pharmacodynamics in man. Int J Clin Pharmacol Ther. 1998;36:581-585.
84. Bertz RJ, Kroboth PD, Kroboth FJ, et al. Alprazolam in young and elderly men: sensitivity and tolerance to psychomotor, sedative, and memory effects. J Pharmacol Exp Ther. 1997;281:1317-1329.
85. Platten HP, Schweizer E, Dilger K, et al. Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients under tooth extraction. Clin Pharmacol Ther. 1998;63:552-560.
86. Boxer R, Yang SX, Hager WD. Congestive heart failure and the elderly. Conn Med. 2003;67:497-503.
87. Aronow WS, Frishman WH, Cheng-Lai A. Cardiovascular drug therapy in the elderly. Heart Dis. 2000;2:151-167.
88. Haji SA, Movahed A. Update on digoxin therapy in congestive heart failure. Am Fam Phys. 2000;62:409-416.
89. Hanratty CG, McGlinchey P, Johnston GD, et al. Differential pharmacokinetics of digoxin in elderly patients. Drugs Aging. 2000;17:353-362.
90. Miura T, Kojima R, Sugiura Y, et al. Effect of aging on the incidence of digoxin toxicity. Ann Pharmacother. 2000;34:427-432.
91. Moore A, Mangoni AA, Lyons D, et al. The cardiovascular system in the aging patient. Br J Clin Pharmacol. 2003;56:254-260.
92. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet. 2005;44:33-60.
93. Abernethy DR, Schwartz JB, Todd EL, et al. Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients altered electrocardiographic and hypotensive responses. Ann Intern Med. 1986;105:329-336.
94. Abernethy DR, Wainer IW, Longstreth JA, et al. Stereo-selective verapamil disposition and dynamics in aging during racemic verapamil administration. J Pharmacol Exp Ther. 1993;266:904-911.
95. Mayo P, Skeith K, Russell AS, et al. Increased S-verapamil plasma concentration in rheumatic arthritis without increased cardiac effect. Br J Clin Pharmacol. 2000;50:605-613.
96. 2+ current by IL-1β in rat ventricular myocytes. Am J Physiol. 1999;276:H141-H148.
97. Kulmatycki KM, Jamali F. Drug disease interactions: role of inflammatory mediators in disease and variability in drug response. J Pharm Pharm Sci. 2005;8:602-625.
98. Cooper HA. Trials of newer approaches to anticoagulation in atrial fibrillation. J Interv Card Electrophysiol. 2004;10(Suppl 1):27-31.
99. Casner PR, Sandoval E. Increased sensitivity to warfarin in elderly Hispanics. J Clin Pharmacol. 2002;42:145-150.
100. Squizzato A, Steidl L, Ageno W. Current issues in the initial phase of warfarin therapy. Recent Prog Med. 2005;96:612-615.
101. Siguret V, Gouin I, Golmard JL, et al. Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients. Rev Med Interne. 2004;25:271-274.
102. Owen JA, Sitar DS, Berger L, et al. Age-related morphine kinetics. Clin Pharmacol Ther. 1983;34:364-368.
103. Wilder-Smith OH. Opioid use in the elderly. Eur J Pain. 2005;9:137-140.
104. Buntin-Mushock C, Phillip L, Moriyama K, et al. Age-dependent opioid escalation in chronic pain patients. Anesth Analg. 2005;100:1740-1745.
105. Wang Y, Mitchell J, Moriyama K, et al. Age-dependent morphine tolerance development in the rat. Anesth Analg. 2005;100:1733-1739.
106. Mintzer J, Targum SD. Psychosis in elderly patients: classification and pharmacotherapy. Psychiatry Neurol. 2003;16:199-206.
107. Jeste DV, Twamley EW. Understanding and managing psychosis in late life. Psychiatric Times. 2003; XX. Available at www.psychiatrictimes.com (accessed July 12, 2006).
108. Finkel S. Pharmacology of antipsychotics in the elderly: a focus on atypicals. J Am Geriatr Soc. 2004;52:S258-S265.
109. van Iersel MB, Zuidema SU, Koopmans RT, et al. Antipsychotics for behavioural and psychological problems in elderly people with dementia: a systematic review of adverse events. Drugs Aging. 2005;22:845-858.
110. Kirkwood CK, Givone DM. Advances in pharmacotherapy of psychotic disorders in the elderly. Consult Pharm. 2003;18:539-550.
111. Taylor M, Turner M, Watt L, et al. Atypical antipsychotics in the real world: a naturalistic comparative outcome study. Scott Med J. 2005;50:102-106.
112. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64:134-143.
113. Aichhorn W, Weiss U, Marksteiner J, et al. Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol. 2005;19:395-401.
114. Bianchetti A, Ranieri P, Margiotta A, et al. Pharmacological treatment of Alzheimer's Disease. Aging Clin Exp Res. 2006;18:158-162.
115. Bianchetti A, Ranieri P, Margiotta A, et al. Pharmacological treatment of Alzheimer's Disease. Aging Clin Exp Res. 2006;18:158-162.
116. Hanlon JT, Artz MB, Pieper CF, et al. Inappropriate medication use among frail elderly inpatients. Ann Pharmacother. 2004;38:9-14.
117. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J General Intern Med. 1999;14:711-717.
118. Allen Maycock CA, Muhlestein JB, Horne BD, et al. Intermountain Heart Collaborative Study. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol. 2002;40:1777-1785.